Published in Infect Immun on October 01, 1998
Interplay between Candida albicans and the mammalian innate host defense. Infect Immun (2012) 1.62
Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells. Infect Immun (2001) 1.34
The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun (2002) 1.28
The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun (2004) 1.25
Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun (2006) 1.01
Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect Immun (2004) 0.98
Complement-mediated neutralization of dengue virus requires mannose-binding lectin. MBio (2011) 0.97
Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis. Infect Immun (2006) 0.90
The pH-regulated antigen 1 of Candida albicans binds the human complement inhibitor C4b-binding protein and mediates fungal complement evasion. J Biol Chem (2011) 0.87
Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans. Mol Immunol (2008) 0.82
Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo. Virulence (2016) 0.80
Influence of mannan and glucan on complement activation and C3 binding by Candida albicans. Infect Immun (2009) 0.78
Identification of human plasma proteins associated with the cell wall of the pathogenic fungus Paracoccidioides brasiliensis. FEMS Microbiol Lett (2013) 0.77
Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Infect Immun (1998) 0.77
Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun (1978) 32.33
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Adherence and receptor relationships of Candida albicans. Microbiol Rev (1991) 4.24
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Purification and structural studies on the complement-system control protein beta 1H (Factor H). Biochem J (1982) 1.91
Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect Immun (1986) 1.88
Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect Immun (1989) 1.76
Structural study of phosphomannan of yeast-form cells of Candida albicans J-1012 strain with special reference to application of mild acetolysis. Arch Biochem Biophys (1989) 1.70
The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan. J Immunol (1981) 1.57
The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol (1983) 1.55
Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation. J Immunol (1978) 1.54
Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infect Immun (1980) 1.48
Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis (1978) 1.46
Role of complement during experimental Candida infection in mice. Infect Immun (1971) 1.46
Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J Immunol (1979) 1.31
Comparison by ELISA of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia (1980) 1.30
The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway. J Immunol (1981) 1.26
Antibody-dependent alternative pathway killing of Haemophilus influenzae type b. Infect Immun (1984) 1.24
Evidence that Candida albicans binds via a unique adhesion system on phagocytic cells in the marginal zone of the mouse spleen. Infect Immun (1992) 1.19
Activation and binding of C3 by Candida albicans. Infect Immun (1987) 1.17
Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect Immun (1996) 1.16
IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J Immunol (1981) 1.10
Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect Immun (1997) 1.05
Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J Immunol (1982) 1.04
Innate and acquired immune responses against Candida albicans in congenic B10.D2 mice with deficiency of the C5 complement component. J Med Vet Mycol (1986) 1.04
Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica. Infect Immun (1989) 1.03
Separate pathways of C activation by measles virus cytotoxic antibodies: subclass analysis and capacity of F(ab) molecules to activate C via the alternative pathway. J Immunol (1978) 1.02
Quantitation of antibody to Candida mannan by enzyme-linked immunosorbent assay. J Lab Clin Med (1983) 1.02
Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand J Immunol (1985) 1.01
Arthropathic group A streptococcal cell walls require specific antibody for activation of human complement by both the classical and alternative pathways. Infect Immun (1986) 0.97
Antibody enhances killing of Tritrichomonas foetus by the alternative bovine complement pathway. Infect Immun (1990) 0.85
Cytotoxicity of human serum for Leishmania donovani amastigotes: antibody facilitation of alternate complement pathway-mediated killing. Infect Immun (1985) 0.83
Lack of a requirement for the Fc region of IgG in restoring pneumococcal opsonization via the alternative complement pathway in sickle cell disease. J Infect Dis (1986) 0.82
Structural requirements of rabbit IgG F(ab')2 fragment for activation of the complement system through the alternative pathway--I. Disulfide bonds. Mol Immunol (1981) 0.81
The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol (1982) 3.92
Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect Immun (1976) 3.41
Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect Immun (1977) 2.84
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun (1987) 2.50
Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun (1984) 2.30
An immunohistochemical method that differentiates Cryptococcus neoformans varieties and serotypes in formalin-fixed paraffin-embedded tissues. Med Mycol (2001) 2.16
Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun (1988) 2.11
Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect Immun (1979) 2.01
Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun (1977) 1.93
Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun (1990) 1.89
Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect Immun (1986) 1.88
Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect Immun (1989) 1.87
Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun (1995) 1.86
Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun (1990) 1.72
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun (1996) 1.71
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect Immun (1981) 1.68
Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect Immun (1980) 1.65
Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect Immun (1979) 1.65
Induction of humoral antibody response by soluble polysaccharide of Cryptococcus neoformans. Mycopathol Mycol Appl (1974) 1.61
Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun (1993) 1.56
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun (1996) 1.53
Binding of cryptococcal polysaccharide to Cryptococcus neoformans. Infect Immun (1984) 1.52
Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.51
Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody. Infect Immun (1972) 1.50
Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol (2001) 1.48
Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J (1994) 1.42
Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun (1992) 1.41
Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect Immun (1979) 1.39
Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol (2000) 1.39
Extracellular deoxyribonuclease production by yeasts. J Bacteriol (1969) 1.37
Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.34
Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule. Infect Immun (1995) 1.31
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun (1997) 1.27
Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect Immun (1994) 1.26
In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J Infect Dis (2001) 1.24
Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages. Infect Immun (1978) 1.20
Activation and binding of C3 by Candida albicans. Infect Immun (1987) 1.17
Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun (1998) 1.16
Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect Immun (1997) 1.12
The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect Immun (1999) 1.11
Antibody interactions with the capsule of Cryptococcus neoformans. Infect Immun (2000) 1.10
Dissociation of a hydrophobic surface from phagocytosis of encapsulated and non-encapsulated cryptococcus neoformans. Infect Immun (1983) 1.05
Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect Immun (1997) 1.05
In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans. Infect Immun (1992) 1.04
Serotyping of Cryptococcus neoformans by dot enzyme assay. J Clin Microbiol (1996) 1.04
Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule. Infect Immun (1993) 1.00
Activation of the alternative complement pathway by fungal melanins. Clin Diagn Lab Immunol (2002) 1.00
Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect Immun (2001) 0.98
Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene. Infect Immun (1997) 0.97
Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans. J Biol Chem (1994) 0.96
Recent advances in biology and immunology of Cryptococcus neoformans. J Med Vet Mycol (1992) 0.91
Binding of Cryptococcus neoformans to heterologously expressed human complement receptors. Infect Immun (1997) 0.91
Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast. Infect Immun (2001) 0.91
T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur J Immunol (2000) 0.88
Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. J Immunol (1998) 0.86
A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock. Infect Immun (2012) 0.85
B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology (1999) 0.83
Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies. Infect Immun (2001) 0.83
Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun (1998) 0.83
Cryptococcus neoformans and Candida albicans regulate CD4 expression on human monocytes. J Infect Dis (1998) 0.81
Interleukin-12 counterbalances the deleterious effect of human immunodeficiency virus type 1 envelope glycoprotein gp120 on the immune response to Cryptococcus neoformans. J Infect Dis (2000) 0.80
A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide. Clin Exp Immunol (2011) 0.80
HIV type 1 envelope glycoprotein gp120 induces development of a T helper type 2 response to Cryptococcus neoformans. AIDS (1999) 0.79
Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Infect Immun (1998) 0.77